Does Anthem (Elevance Health) Cover Mounjaro?

Anthem's Coverage Policy for Mounjaro

Anthem (Elevance Health) includes Mounjaro (tirzepatide) on its commercial formulary for the FDA-approved indication of type 2 diabetes mellitus. The FDA approved tirzepatide in May 2022 as a once-weekly injectable for glycemic control in adults with type 2 diabetes. Coverage requires prior authorization and documented step therapy on every Anthem commercial plan type, including PPO, HMO, and EPO products.

What the Formulary Classification Means

On most Anthem formularies, Mounjaro lands on Tier 4 (non-preferred specialty) or Tier 5 (specialty). This placement means higher cost-sharing compared to preferred generics like metformin (Tier 1) or preferred brand GLP-1 agents that Anthem may favor. Your specific tier depends on which Anthem plan your employer selected. Members can verify placement by logging into the Anthem member portal and searching the drug formulary tool, or by calling the number on the back of their insurance card.

Diabetes vs. Weight Loss: A Critical Distinction

Anthem draws a firm line between type 2 diabetes and weight management. If your prescriber submits a PA request citing obesity or weight loss as the primary diagnosis, Anthem will deny the claim. Tirzepatide does have a separate FDA approval under the brand name Zepbound for chronic weight management, but Anthem's commercial medical policies typically exclude anti-obesity medications or place them under a separate, more restrictive benefit category. Members seeking weight-loss coverage should ask their benefits coordinator whether their specific plan includes an anti-obesity medication rider.

Prior Authorization Requirements

Anthem requires prior authorization for every Mounjaro prescription. The PA process confirms medical necessity and verifies that the member has attempted first-line therapies. Expect the review to take 3 to 5 business days for standard requests. Urgent requests tied to clinical deterioration can be processed within 24 to 72 hours.

Documentation Your Prescriber Must Submit

To secure approval, the prescribing clinician needs to provide:

• A confirmed diagnosis of type 2 diabetes (ICD-10 code E11.x)
• Current HbA1c value, typically 7.0% or higher despite first-line therapy
• Documentation of metformin use for at least 90 days (or documented intolerance/contraindication)
• Body mass index, renal function (eGFR), and any relevant comorbidities
• Clinical rationale explaining why tirzepatide is preferred over formulary-preferred GLP-1 alternatives

The SURPASS-2 trial (N=1,879) demonstrated that tirzepatide 15 mg reduced HbA1c by 2.58% compared to 1.86% with semaglutide 1 mg at 40 weeks [1]. Prescribers can reference this head-to-head data when justifying tirzepatide over other GLP-1 receptor agonists that Anthem may prefer on formulary.

Common Reasons for PA Denial

The most frequent denial triggers include:

• Missing metformin trial documentation (or no documented contraindication such as eGFR <30 mL/min/1.73m²)
• HbA1c below plan threshold (some Anthem plans require 7.5% or higher)
• Diagnosis coded as obesity (E66.x) rather than type 2 diabetes
• Incomplete lab work submitted with the request
• No clinical notes explaining why a preferred-tier GLP-1 agent was inadequate

Step Therapy: What Anthem Requires First

Anthem's step therapy protocol for Mounjaro follows a predictable sequence. The insurer requires failure of, or documented intolerance to, at least one first-line medication before authorizing tirzepatide.

The Typical Step Therapy Ladder

Step 1: Metformin at maximally tolerated dose (typically 1,500 to 2,000 mg daily) for a minimum of 90 days. The American Diabetes Association Standards of Care recommend metformin as initial pharmacotherapy for most adults with type 2 diabetes [2].

Step 2: Some Anthem plans require trial of a preferred-tier GLP-1 receptor agonist (often dulaglutide or a preferred semaglutide product) before approving tirzepatide. This second step varies by plan. Not all Anthem products enforce it.

Step 3: If steps 1 and 2 fail to achieve glycemic targets, or if the member experiences intolerable side effects, Mounjaro becomes eligible for approval.

Bypassing Step Therapy

Certain clinical scenarios allow prescribers to request a step therapy exception:

• Documented metformin intolerance (persistent GI side effects at doses above 500 mg, lactic acidosis risk, or eGFR <30)
• Severe hyperglycemia at diagnosis (HbA1c above 10%) requiring rapid glycemic reduction
• Concurrent cardiovascular disease where dual GIP/GLP-1 receptor agonism offers a distinct clinical rationale
• Prior use and failure of the required step medications at another insurer within the past 12 months

The Endocrine Society's 2023 guidelines on pharmacologic treatment of obesity note that dual incretin agonists like tirzepatide represent a distinct mechanism from single GLP-1 receptor agonists, which may support exception requests when a GLP-1 RA alone proved insufficient [3].

Cost Breakdown With Anthem Coverage

Understanding what you will actually pay requires knowing your plan's cost-sharing structure. Mounjaro's list price of $1,023 per month is the starting point before any insurance benefit applies.

Typical Out-of-Pocket Scenarios

| Anthem Plan Type | Formulary Tier | Estimated Monthly Copay | Notes | |---|---|---|---| | Commercial PPO (large employer) | Tier 4 | $50, $100 | After PA approval | | Commercial HMO | Tier 4/5 | $75, $150 | May require specialist referral | | Exchange (Marketplace) Silver | Tier 5 | $100, $150+ | Higher cost-sharing typical | | Anthem Medicare Advantage | Varies | $47, $100 (coverage gap applies) | Part D formulary rules apply |

These figures represent approximations. Actual cost-sharing depends on your plan's deductible status, coinsurance percentage, and whether you have reached your out-of-pocket maximum.

Manufacturer Savings Card Stacking

Eli Lilly offers a Mounjaro Savings Card that can reduce out-of-pocket costs to as little as $25 per month for eligible commercially insured patients. Key eligibility rules:

• Must have commercial insurance (not Medicare, Medicaid, or Tricare)
• Prescription must be for an FDA-approved indication
• Maximum savings of $150 per monthly prescription fill (terms change periodically)

Members with Anthem commercial plans can typically stack the savings card on top of their insurance benefit. If your Anthem copay after PA is $100, the savings card could reduce your actual payment to $25. Confirm current savings card terms directly with Lilly's program, as benefit caps and eligibility criteria update annually.

How to Appeal an Anthem Denial

A denied PA is not the final word. Anthem provides a structured appeal process, and success rates improve significantly with targeted clinical documentation.

Internal Appeal Process

Step 1: Request the denial letter. Anthem must provide a written explanation citing the specific clinical criteria your request failed to meet. Review this letter carefully. It identifies exactly what documentation to add.

Step 2: File an internal appeal within 180 days of the denial. Your prescriber should submit a peer-to-peer review request and include:

• Updated lab values (HbA1c, renal function, lipid panel)
• Clinical notes documenting step therapy failure or intolerance
• Published evidence supporting tirzepatide for the member's specific clinical profile
• A letter of medical necessity referencing trial data

In SURPASS-2 (N=1,879), patients on tirzepatide 15 mg achieved an HbA1c of 5.5% at 40 weeks, with 92% reaching the ADA target of <7.0% [1]. This response rate exceeded semaglutide 1 mg (81%) in the same trial. Citing specific efficacy numbers strengthens appeal letters compared to vague statements about "superior outcomes."

External Review Through State IRO

If Anthem's internal appeal fails, every state allows members to request an Independent Review Organization (IRO) evaluation. The IRO is a third-party panel that reviews your case independently of Anthem. Key points:

• You must exhaust at least one level of internal appeal before requesting external review (two levels in some states)
• The external review decision is binding on Anthem
• Timelines vary by state: typically 45 days for standard review, 72 hours for expedited cases involving urgent medical need
• There is no cost to the member for filing an external review

Tips That Improve Appeal Success

Prescribers who include peer-reviewed data in appeal letters see higher overturn rates. The SURPASS program enrolled over 20,000 participants across multiple phase 3 trials, providing a broad evidence base [4]. Dr. Juan Pablo Frias, principal investigator for SURPASS-2, noted that tirzepatide's dual GIP and GLP-1 receptor agonism "represents a differentiated mechanism that achieved glycemic targets in patients who had not responded adequately to GLP-1 receptor agonists alone" [1].

Beyond clinical evidence, procedural accuracy matters. Ensure the appeal is filed within the deadline, all required forms are completed, and the member's written consent for the appeal is on file.

Anthem Medicare Advantage and Mounjaro

Medicare Advantage plans administered by Anthem follow Part D formulary rules, which differ from commercial plan policies. Mounjaro coverage under Medicare Part D requires the same type 2 diabetes diagnosis but follows CMS-regulated utilization management criteria rather than Anthem's commercial PA protocols.

Key Differences From Commercial Plans

• Manufacturer savings cards cannot be used with Medicare plans (federal anti-kickback statute)
• The Part D coverage gap ("donut hole") applies, meaning members pay 25% coinsurance during the gap phase
• Low-Income Subsidy (LIS) and Extra Help programs may reduce costs for eligible beneficiaries
• Step therapy requirements may differ from Anthem's commercial formulary

Medicare Advantage members should request a Coverage Determination from Anthem before filling the prescription. If denied, the appeal follows CMS timelines: 7 days for standard redetermination, 72 hours for expedited.

Alternatives if Anthem Denies Mounjaro

When coverage is denied and appeals are exhausted, several alternatives exist. Each carries different cost, efficacy, and access profiles.

Preferred Formulary GLP-1 Options

Anthem's preferred-tier GLP-1 agents (which vary by plan year) often include dulaglutide (Trulicity) or a preferred semaglutide product. These carry lower copays and easier PA pathways. The ADA Standards of Care support GLP-1 receptor agonists as a class for patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk [2].

Compounding and Cash-Pay Pathways

Some patients explore compounded tirzepatide through specialty pharmacies, though this raises quality and safety considerations. The FDA has issued guidance on compounded GLP-1 receptor agonists, and patients should verify that any compounding pharmacy is registered with the FDA and their state board of pharmacy [5].

Patient Assistance Programs

Eli Lilly's Lilly Cares Foundation provides free Mounjaro to uninsured or underinsured patients who meet income thresholds (typically at or below 400% of the federal poverty level). Application requires prescriber involvement and proof of income documentation.

Understanding Tirzepatide's Clinical Profile

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist. This dual mechanism distinguishes it from single-target GLP-1 agents like semaglutide or dulaglutide.

Efficacy Data From SURPASS Trials

The SURPASS clinical program included five phase 3 trials evaluating tirzepatide across the type 2 diabetes treatment spectrum. In SURPASS-2, tirzepatide 15 mg reduced body weight by 12.4 kg compared to 6.2 kg with semaglutide 1 mg at 40 weeks [1]. The SURPASS-4 trial (N=2,002) showed sustained HbA1c reductions of 2.24% with tirzepatide 15 mg versus 1.53% with insulin glargine over 52 weeks [4].

Safety Considerations

The most common adverse events with tirzepatide are gastrointestinal: nausea (12 to 18%), diarrhea (12 to 17%), and decreased appetite (5 to 11%). These effects are dose-dependent and typically diminish after 4 to 8 weeks of continued use. Rare but serious risks include pancreatitis and, in animal studies, medullary thyroid carcinoma (leading to a boxed warning). Tirzepatide is contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [6].

The Endocrine Society recommends monitoring for these adverse effects during dose titration and maintaining regular follow-up during treatment [3].